Indeed, the current classification moves to the right direction by adopting a clinically meaningful way of thinking and avoiding unnecessary pathophysiological implications; PH owing to left heart disease (Group 2) and chronic thromboembolism (Group 4) are good examples. In this context, sarcoidosis, PLCH and LAM (Group 5.2) represent disorders that, according to the current evidence, are associated with PH mainly due to lung involvement and, therefore, we propose their inclusion in the third category (PH owing to lung disease and/or hypoxia) in any future classification scheme.